Novo Holdings invests in proteomics technology company, Evosep

COPENHAGEN, DENMARK — Novo Holdings, a leading international life science investor, today announced a $40m investment in Evosep, the bioscience company leading the standardisation of proteomics for clinical use.

The proceeds from the investment by Novo Holdings will be used to advance clinical applications of proteomics enabled by Evosep’s standardised liquid chromatography platform. The new funds will also allow Evosep to further expand its presence globally, especially in the rapidly growing US market, providing more customers a solution for robust, high-throughput proteomics.

Read more…